<DOC>
	<DOCNO>NCT00948753</DOCNO>
	<brief_summary>This study investigate effectiveness safety Maraviroc ( oral medication give twice daily give addition standard GVHD prophylaxis ) prevent Graft versus Host Disease ( GVHD ) patient undergo non-myeloablative allogeneic stem-cell transplantation ( SCT ) . Subjects receive Maraviroc bid ( addition standard GVHD prophylaxis ) begin last dose chemotherapy condition regimen day 30 stem-cell infusion .</brief_summary>
	<brief_title>Maraviroc Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>patient schedule undergo nonmyeloablative allogeneic stemcell transplantation . meet institutional eligibility criterion allogeneic SCT . Significant criterion : Renal function : Serum creatinine &lt; 2 ; calculate creatinine clearance &gt; 40 mL/min/1.72m2 ; Hepatic function : Baseline direct bilirubin , ALT AST low three time upper limit normal ; Pulmonary disease : FVC FEV1 &gt; 40 % predict ; Cardiac ejection fraction &gt; 40 % . Patients expect available followup institution least 100 day transplant Patients undergoing standard nonmyeloablative SCT Flu/Bu condition Tax/MTX GVHD prophylaxis Patients uncontrolled bacterial , viral fungal infection Patients take strong inducer inhibitor CYP450A4 Patients receive investigational drug GVHD Women pregnant , plan become pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Graft-versus-host disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>Maraviroc</keyword>
	<keyword>non-myeloablative allogeneic stem-cell transplantation</keyword>
	<keyword>Hematopoietic stem cell transplantation</keyword>
</DOC>